Avoro Capital Advisors LLC
Institutional investor · Portfolio as of Q3 2019
Top Holdings33 positions
MIRATI THERAPEUTICS INC | 3.8M | $292.2M | 12.2% | — | — | 3 qtrssince 2019-Q1 | Decreased 0 |
IMMUNOMEDICS INC | 21M | $278.5M | 11.6% | — | — | 3 qtrssince 2019-Q1 | Unchanged 0 |
IOVANCE BIOTHERAPEUTICS INC COM | 10.6M | $192.9M | 8.0% | $9.82 | +83.21% | 3 qtrssince 2019-Q1 | Decreased 0 |
ASCENDIS PHARMA A/S | 2M | $189.8M | 7.9% | $117.47 | -18.12% | 3 qtrssince 2019-Q1 | Unchanged 0 |
BIOMARIN PHARMACEUTICAL INC | 2.4M | $164.3M | 6.9% | $84.82 | -19.46% | 3 qtrssince 2019-Q1 | Increased 69 |
AMARIN CORP PLC | 8.5M | $129.2M | 5.4% | — | — | — | Increased 67 |
SAREPTA THERAPEUTICS INC | 1.7M | $126.4M | 5.3% | $115.87 | -35.27% | 3 qtrssince 2019-Q1 | Increased 70 |
HORIZON THERAPEUTICS PUB L | 4M | $108.9M | 4.5% | — | — | 2 qtrssince 2019-Q2 | Unchanged 0 |
ARGENX SE | 835,000 | $95.2M | 4.0% | $124.84 | -8.72% | 3 qtrssince 2019-Q1 | Decreased 0 |
AMICUS THERAPEUTICS INC | 11.1M | $89M | 3.7% | $13.00 | -37.93% | 3 qtrssince 2019-Q1 | Increased 62 |
MYOKARDIA INC | 1.6M | $81M | 3.4% | — | — | 3 qtrssince 2019-Q1 | Increased 63 |
ZOGENIX INC | 1.9M | $75.1M | 3.1% | — | — | 3 qtrssince 2019-Q1 | Decreased 0 |
ATHENEX INC | 5.9M | $71.7M | 3.0% | — | — | 2 qtrssince 2019-Q2 | Increased 64 |
TRICIDA INC | 2.2M | $67.9M | 2.8% | — | — | 3 qtrssince 2019-Q1 | Unchanged 0 |
PACIRA BIOSCIENCES INC COM | 1.6M | $60.9M | 2.5% | $39.52 | -8.11% | 3 qtrssince 2019-Q1 | Increased 83 |
KARYOPHARM THERAPEUTICS INC | 6.1M | $58.2M | 2.4% | — | — | — | New 77 |
GLOBAL BLOOD THERAPEUTICS IN | 1M | $48.5M | 2.0% | — | — | 3 qtrssince 2019-Q1 | Increased 54 |
ACADIA PHARMACEUTICALS INC | 887,500 | $31.9M | 1.3% | $26.85 | +36.98% | 3 qtrssince 2019-Q1 | Decreased 0 |
BIODELIVERY SCIENCES INTL INC | 7.4M | $31.3M | 1.3% | — | — | 3 qtrssince 2019-Q1 | Unchanged 0 |
MADRIGAL PHARMACEUTICALS INC COM | 360,000 | $31M | 1.3% | $122.42 | -29.57% | 3 qtrssince 2019-Q1 | Unchanged 0 |
Avoro Capital Advisors LLC manages $2.4B across 33 positions as of Q3 2019. Top holdings: MRTX (12.2%), IMMU (11.6%), IOVA (8.0%). Fund DNA: Concentrated Value. HoldingsIntel Score: 2.5/5.0.
Added 3 new positions, exited 3, increased 9, trimmed 7. Top move: PCRX (INCREASED, conviction 83). Portfolio: $2.4B across 33 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR